Genmab | GEN - Umsatzkosten

Aktienkurs
1,637.00
Täglich Wechseln
-8.00 -0.49%
Monatlich
-10.67%
Jährlich
20.06%
Q1 Prognose
1,614.31




Umsatzkosten Veränderung Datum
Agios Pharmaceuticals USD 1.88M 199K 2025-12
Almirall EUR 191.5M 2.29M 2025-12
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.79B 128M 2025-12
argenx SE USD 149.69M 40.26M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
Bayer EUR 4.5B 194M 2025-12
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Demant DKK 2.89B 188M 2025-12
Exelixis USD 26.48M 7.91M 2025-12
Fresenius Medical Care EUR 3.68B 38.37M 2025-12
Galapagos EUR 455K 84.28M 2025-12
Genmab DKK 81M 23M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
GN Store Nord DKK 2.24B 338M 2025-12
GRIFOLS EUR 1.29B 163.12M 2025-12
Hikma Pharmaceutical USD 959M 492.5M 2025-12
Insmed USD 46.16M 15.25M 2025-12
Lonza CHF 2.28B 189M 2025-06
Merck EUR 2.29B 183M 2025-12
Novartis USD 3.54B 3M 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 4.29B 421M 2025-12
UCB EUR 1.07B 146M 2025-12